|
Seton Hall Law Review Symposium
|
Keynote Speaker:
Daniel Meron, General Counsel United States Department of Health
and Human Services
Panel I: The Effect of the FDA Drug Approval Process and
Intellectual Property Protections on Domestic Public Health and
Drug Access
Margaret Gilhooley, Professor of Law, Seton Hall Law School
Michael B. Kades, Senior Attorney, Federal Trade Commission
Thomas (Tim) Greaney, Chester A. Myers Professor at Law,
Saint Louis University School of Law, and Visiting Professor,
Seton Hall Law School
Audio
(right click and save target locally to play)
For a case finding that there was no failure by Celebrex to
provide cardiovascular warnings before FDA's call for a Black
Box warning in 2005, see:
In re Bextra and Celebrex Marketing Sales Practices and
Product Liability Litigation, 2006 WL 2374742 (N.D. Cal.
2006).
Panel II: How FDA Regulations, Intellectual Property Protections, and Drug Innovation Affect Global Public Health Initiatives
Shamnad Basheer, Frank H. Marks Visiting Associate
Professor of Law, George Washington University Law School
William (Terry) Fisher, Hale and Dorr Professor of
Intellectual
Property Law, Harvard Law School
Frank Pasquale, Associate Professor of Law, Seton Hall
Law
School
Audio (right click and save target locally to play)
Panel III: The Link Between Health Economics and FDA Regulations and Policies
Matthew D. Adler, Leon Meltzer Professor of Law,
University of
Pennsylvania Law School
Benjamin P. Falit, J.D., Candidate for M.D.,
2010, Yale University School of
Medicine
Kevin Outterson, Associate Professor of Law, West
Virginia
College of Law
Audio (right click and save target locally to play)